Minimal residual disease in breast cancer: in blood veritas
- PMID: 24658155
- DOI: 10.1158/1078-0432.CCR-14-0370
Minimal residual disease in breast cancer: in blood veritas
Abstract
A blood-based molecular test might direct recommendations for systemic therapies in patients with early-stage breast cancer undergoing surgery with curative intent. A new study suggests that droplet digital PCR (ddPCR) can be used to detect cancer-specific DNA alterations in plasma with sensitivity suitable for monitoring minimal residual disease.
©2014 American Association for Cancer Research.
Comment on
-
Detection of cancer DNA in plasma of patients with early-stage breast cancer.Clin Cancer Res. 2014 May 15;20(10):2643-2650. doi: 10.1158/1078-0432.CCR-13-2933. Epub 2014 Feb 6. Clin Cancer Res. 2014. PMID: 24504125 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical